Compare Apple Inc (AAPL) vs Novavax Inc (NVAX) Price & Performance

Apple (AAPL) trades at $310.09, down 0.82% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $2.01 exceeding the $1.95 estimate. Revenue for 2025 reached $416.16 billion, driving a net income margin of 26.91%. Analysts maintain a consensus buy rating with a $329.62 price target, citing Apple's massive device base as an AI opportunity.

The outlook remains positive given earnings momentum and a $0.27 dividend, but risks include potential Q2 2026 earnings miss concerns and union disputes. Valuation multiples like P/E of 37.61 suggest premium pricing, requiring sustained growth to justify upside. Institutional holdings show mixed activity, with some trimming positions amid high RSI levels indicating overbought conditions near-term.

Novavax (NVAX) trades at $9.46, down 2.87% on the day, with a bullish technical signal from moving averages. The company reported strong revenue of $1.12B in 2025 and has beaten EPS estimates for three consecutive quarters. Analyst consensus is bullish with a $14.00 price target, though negative cash flow and shareholder equity remain concerns. Recent news highlights investor attention and participation in healthcare conferences.

Outlook: Potential upside exists from continued earnings beats and vaccine demand, but risks include persistent cash burn, high debt, and competitive pressures. The stock offers speculative growth opportunity amid volatile biotech sentiment, requiring careful risk assessment.